After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...
Hosted on MSN
BD’s (NYSE:BDX) Q1 CY2026 sales beat estimates
Medical technology company Becton, Dickinson and Company (NYSE:BDX) announced in Q1 CY2026, with sales up 5.2% year on year to $4.71 billion. Its non-GAAP profit of $2.90 per share was 4.5% above ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
BD (Becton, Dickinson and Company) has agreed to combine its biosciences and diagnostic solutions business with Waters Corporation, creating a new life science and diagnostics company. The agreement ...
Medical technology company Becton, Dickinson and Company (NYSE:BDX) announced better-than-expected revenue in Q1 CY2026, with sales up 5.2% year on year to $4.71 billion. Its non-GAAP profit of $2.90 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results